Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)

  • Sally Baron-HayEmail author
  • Matti Aapro
  • Alberto Bernareggi
  • Lee Schwartzberg
Open Access
Original Article



The administration timing of antiemetic and chemotherapeutic regimens is often determined by regulatory indications, based on registration studies. Oral NEPA, fixed combination of the neurokinin-1 receptor antagonist (NK1RA) netupitant and the 5-hydroxytryptamine-3 RA (5-HT3RA) palonosetron, is recommended to be administered approximately 60 min before chemotherapy. Reducing chair time for chemotherapy administration at oncology day therapy units would improve facility efficiency without compromising patient symptom management. The objective was to determine if oral NEPA can be administered closer to chemotherapy initiation without compromising patient symptom management.


NK1 receptor occupancy (NK1RO) time course in the brain was determined using positron emission tomography; netupitant and palonosetron plasma concentration-time profiles were described by pharmacokinetic (PK) models; and the rate, extent, and duration of RO by netupitant and palonosetron were predicted by pharmacodynamic modeling. Clinical efficacy data from a pivotal study in cisplatin and oral NEPA-receiving patients were reviewed in the context of symptom management.


Striatal 90% NK1RO, assumed to correlate with NK1RA antiemetic efficacy, was predicted at netupitant plasma concentration of 225 ng/mL, reached at 2.23 h following NEPA administration. Palonosetron 90% 5-HT3RO was predicted at a 188-ng/L plasma concentration, reached at 1.05 h postdose. The mean time to first treatment failure for the 1.5% of NEPA-treated patients without complete response receiving highly emetogenic chemotherapy was 8 h. Antiemetic efficacy was sustained over 5 days despite the expected decrease of NK1RO and 5-HT3RO.


Results suggest that administering oral NEPA closer to initiation of cisplatin administration would provide similar antiemetic efficacy. Prospective clinical validation is required.


Chemotherapy-induced nausea and vomiting CINV NEPA Netupitant Palonosetron Administration timing 


Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing side effects of emetogenic chemotherapy and can negatively impact quality of life and overall survival of cancer patients [1, 2, 3]. Advances in antiemetic research have improved the therapeutic options for the prevention of CINV [4]. However, complete control of emesis, and especially of nausea, is still not achieved in many cancer patients [5, 6]. The American Society of Clinical Oncology guidelines [7], National Comprehensive Cancer Network [8], and the Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology guidelines [9] recommend the triple combination of a 5-hydroxytryptamine-3 receptor antagonist (5-HT3RA), a neurokinin-1 (NK1)RA, and dexamethasone for CINV prevention associated with highly emetogenic chemotherapy (HEC), anthracycline-cyclophosphamide (AC)-based regimens, and carboplatin regimens, with the addition of olanzapine to the triple combination discussed under specific conditions. Finally, patients treated with moderately emetogenic chemotherapy should receive a 5-HT3RA and dexamethasone [7, 8, 9], or the triplet NK1RA–5-HT3RA–dexamethasone combination if they present with additional risk factors or for whom 5-HT3RA and dexamethasone alone fail [8].

CINV is classified as acute or delayed, depending on the timing of its occurrence after the start of chemotherapy administration [10]. The acute phase is defined as the 24 h following chemotherapy and is largely mediated by serotonin activation of 5-HT3 receptors in the intestine, and, to a lesser extent, by activation of centrally located 5-HT3 receptors in the area postrema and nucleus tractus solitarius [11, 12], while the delayed phase is defined as the 25–120 h after chemotherapy and is predominantly driven by substance P activation of NK1 receptors in the area postrema and the nucleus tractus solitarius [10]. Crosstalk between 5-HT3 and NK1 receptors could also contribute to CINV [13]. Generally, 5-HT3RAs have proven highly effective in controlling CINV in the acute phase but poor at control in the delayed phase [14, 15]. Conversely, NK1RAs are most effective in the prevention of CINV during the delayed phase [4]. Several chemotherapeutic agents, such as cisplatin, can induce both acute and delayed CINV [16].

Antiemetic prophylaxis is administered prior to the start of chemotherapy. Among the factors affecting the administration convenience of the chosen antiemetic regimen are the precise timing of administration, the number of agents, the number of doses, and the number of days of treatment. Minimizing the time lapse between the administration of antiemetic regimens and of chemotherapeutic treatments could benefit health care centers and patients. With chair time being a significant issue for busy oncology day therapy units, reducing the time patients occupy a treatment chair for chemotherapy administration could improve facility efficiency without compromising patient symptom management.

Oral NEPA is the first fixed-combination antiemetic, composed of the highly selective NK1RA netupitant (300 mg) and the pharmacologically and clinically distinct 5-HT3RA palonosetron (0.5 mg) [4, 13]. Oral NEPA uniquely targets two critical emetic pathways and provides protection against both acute and delayed CINV [17, 18, 19]. In the registration trials, oral NEPA plus dexamethasone offered superior CINV control in patients receiving cisplatin- and AC-based chemotherapy, compared with oral palonosetron plus dexamethasone [17, 18]. In these studies, NEPA and palonosetron were both administered as a single oral dose approximately 60 min prior to chemotherapy on day 1. The timing for NEPA administration was chosen on the basis of the design used in prior registration studies of aprepitant, the first approved NK1RA [20, 21], while no clinical data supporting this choice are available. As an alternative for patients who cannot swallow oral medication, an intravenous formulation of NEPA (fosnetupitant 235 mg/palonosetron 0.25 mg) administered as a 30-min infusion before chemotherapy has been developed and approved by the US Food and Drug Administration [22] for patients receiving HEC, and it is currently being evaluated in the AC setting.

The convenience of NEPA dosing could be improved by allowing flexibility in the timing of its administration. The start of antiemetic activity is assumed to be related to the time elapsed from drug administration to occupancy of target receptors above a therapeutic threshold, in the relevant regions of the central (CNS) and peripheral (PNS) nervous system. A positron emission tomography (PET) study in humans using aprepitant found that the highest concentration of NK1 receptors in the brain was in the striatum and demonstrated a good correlation between > 90% NK1 receptor occupancy (RO) in the striatum at therapeutic doses and antiemetic efficacy [23]. Consequently, 90% RO in the striatum has become a recognized threshold correlating with NK1RA efficacy [23] and is an accepted surrogate marker for effective NK1RA interaction with NK1 receptors in the area postrema and nucleus tractus solitarius. In the present analysis, the same > 90% 5-HT3RO in relevant tissues of the CNS and PNS [12, 24] was assumed as the threshold required for palonosetron antiemetic effect.

Data from previous pharmacokinetic (PK) and pharmacodynamic (PD) studies carried out during the development of NEPA were used to establish here a PK/PD model-based analysis of NK1- and 5-HT3RO in their respective relevant tissues. Clinical data from a pivotal trial in patients receiving cisplatin-based chemotherapy [17] were evaluated to establish if a correlation could be made between the PK/PD model estimates and the clinical data. As cisplatin is ranked among the most emetogenic chemotherapeutic agents and with emetic activity in the acute and delayed periods [16, 25, 26], this would provide data applicable to broader chemotherapeutic regimens.


Study design (Fig. 1) [17, 27, 28]

Data used for PK/PD modeling of netupitant and palonosetron in this analysis were obtained from previous preclinical and clinical studies performed during the development of oral NEPA and palonosetron.
Fig. 1

Design of studies included for the PK/PD modeling and for the correlation with antiemetic clinical efficacy [17, 27, 28]. BMI, body mass index; CP, complete protection (CR and no significant nausea); CR, complete response (no emesis, no rescue medication); HEC, highly emetogenic chemotherapy; LEC, low emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; NK1, neurokinin-1; oral NEPA, 300 mg netupitant/0.50 mg palonosetron; PD, pharmacodynamic; PET, positron emission tomography; PK, pharmacokinetics

PD data characterizing the interaction of netupitant with NK1 receptors in the brain were from a single-dose, open-label PET study in six healthy adult males randomized to receive oral netupitant at 100-, 300-, or 450-mg dose (two subjects/dose) [27]. Together with oral netupitant, subjects received a highly selective, high-affinity NK1RA PET tracer, [11C]-GR205171, as an intravenous bolus injection at baseline, and at approximately 6, 24, 48, 72, and 96 h after dosing with netupitant. The injections were followed by 60-min PET scans. This procedure allowed the evaluation of netupitant brain penetration, the rate and extent of netupitant interaction with NK1 receptors in different brain regions, and the receptor washout rate. From this PET study, a maximum effect (Emax) model was established to relate NK1RO as a function of netupitant plasma concentration. Through the model, the time required to achieve the 90% NK1RO in the striatum was predicted.

PD data characterizing the interaction of palonosetron with 5-HT3 receptors in tissues were from preclinical studies in NG-108-15 [29] and in HEK 293 cell membranes stably expressing 5-HT3A and 5-HT3B receptors [30].

PK modeling of netupitant and palonosetron plasma concentration-time profiles was based on two-compartment model fitting to mean curves observed in an open-label, randomized phase I study in 22 healthy adults aimed at testing the effect of food on the PK of netupitant and palonosetron [28]. The subjects received single doses of oral NEPA in a fed or fasted state in the initial treatment period and in the alternative state in the following treatment period after a washout of 28 days. Mean netupitant and palonosetron plasma concentration-time curves used for PK modeling were from subjects receiving oral NEPA in the fasted state.

Netupitant and palonosetron PK/PD modeling results were correlated with clinical data from the multinational, randomized, double-blind, parallel group, phase II study in 694 chemotherapy-naive cancer patients scheduled to receive cisplatin-based HEC [17]. This study compared antiemetic efficacy and safety of three different oral doses of netupitant (100, 200, and 300 mg) plus 0.5 mg palonosetron, all given on day 1. A standard 3-day aprepitant plus intravenous ondansetron 32-mg regimen was included as an exploratory arm. All patients received a single oral dose of 12 mg dexamethasone 30 min before cisplatin on day 1 and 4 mg twice daily on days 2–4.

The primary efficacy endpoint was complete response (CR; no emesis, no rescue medication) during the overall phase (0–120 h following chemotherapy). Efficacy analysis results from 135 chemotherapy-naive patients receiving 300 mg netupitant plus 0.5 mg palonosetron (the approved oral NEPA dose) 60 min before cisplatin on day 1 were used to establish clinical correlations with the outcomes from PK/PD modeling analyses.

Detailed design, methods, and patient eligibility criteria for the clinical studies have been published previously [17, 27, 28]. For each, the relevant study protocols were approved by the corresponding ethical review committees, and sites participating in the studies followed the International Conference on Harmonization E6 Good Clinical Practice guidelines, Declaration of Helsinki principles, and local laws and regulations.

Netupitant PK/PD analysis

In the PET study, the extent of NK1RO in different brain regions (striatum, lateral and medial temporal cortex, occipital and frontal cortex, and anterior cingulate) was determined by PET scans following single oral dose administration of netupitant [27].

Blood samples for the determination of netupitant plasma concentrations were collected at the following time points: predose 1, 2, 3, 4, 4.5, 5, 5.5, and 12 h postdose, immediately before the PET scan (6, 24, 48, 72, and 96 h postdose), and immediately after the PET scan (7, 25, 49, 73, and 97 h postdose). Parameter values and the precision of the estimates are reported in the paper by Spinelli et al. [27].

For all subjects, individual NK1RO observations in the striatum and other brain regions were correlated with the respective netupitant plasma concentrations by sigmoid Emax modeling (Eq. 1):
$$ \mathrm{RO}\ \left(\%\right)=\frac{E_{max}\times {C}^{\upgamma}}{EC_{50}^{\upgamma}+{C}^{\upgamma}} $$
where Emax is the maximal NK1RO, EC50 is the plasma concentration at which 50% of Emax is reached, C is the netupitant plasma concentration at any time, and γ is a slope parameter reflecting the shape of the curve. The values of Emax, EC50, and γ for each brain region were estimated by fitting the sigmoid Emax model to the experimental RO values as a function of netupitant plasma concentrations for all subjects and all doses simultaneously, using the software WinNonlin Professional Edition Version 4.1.b (Pharsight Corporation, Mountain View, CA).
The netupitant plasma concentration required to achieve 90% NK1RO, C90%, in the striatum was then predicted by Eq. 2, derived from Eq. 1:
$$ {C}_{90\%}=\sqrt[\gamma ]{\frac{90\%\times {EC}_{50}^{\gamma }}{E_{max}-90\%}} $$
The time required to reach C90% after administration of 300-mg netupitant was estimated through the PK model (Eq. 3) obtained by fitting a two-compartment open model, with first-order absorption, first-order elimination and lag time, to mean plasma netupitant concentration using the PK software Phoenix WinNonlin version 6.4 (Certara, Princeton, NJ).
$$ {C}_t=A\times {e}^{-{\uplambda}_1\times t}+B\times {e}^{-{\uplambda}_2\times t}-C\times {e}^{-{K}_{01}\times t} $$
where Ct represents netupitant plasma concentration at any time, A, B, and C are hybrid constants, λ1 and λ2 are disposition rate constants, K01 is the absorption rate constant, and t is time. Mean plasma netupitant concentration-time curves were obtained from 22 healthy adults enrolled in the above-mentioned PK study [31]. The two-compartment model described by Eq. 3 was fitted to mean plasma concentration-time data of subjects in fasted state by iterative nonlinear regression analysis based on the minimization of the objective function until convergence. The weighted least squares analysis was performed using 1/C(pred)2 as a weighting factor, where C(pred) is the predicted concentration. Goodness of fit was established on the basis of plots of observed vs. predicted concentrations, plots of weighted residuals, and conventional criteria, including the weighted sum of squared residuals, the Akaike Information Criterion, and the Schwarz Bayesian Criterion.

Palonosetron PK/PD analysis

Palonosetron is a potent 5-HT3RA that exhibits allosteric binding and positive cooperativity upon binding to 5-HT3 receptors in HEK 293 cells [30]. In saturation-binding studies in NG-108-15 cell membranes, palonosetron showed a mean affinity (pKi) value of 10.45 M at the 5-HT3 receptor [29]. Assuming competitive inhibition, the palonosetron EC50 can be assumed to be approximately twofold the Ki [32]. Hence,
$$ {\mathrm{EC}}_{50}=2\times {10}^{-10.45}\mathrm{M}=\kern0.5em 0.071\ \mathrm{nM}=21\ \mathrm{ng}/\mathrm{L} $$

Interaction kinetics was modeled using Eq. 1, where Emax is the maximum palonosetron 5-HT3RO, assumed to be 100%, EC50 is the palonosetron plasma concentration at which 50% Emax is achieved, C is palonosetron concentration in plasma at any time, and γ is a slope parameter, assumed to be 1 (the sigmoid Emax model reduces to a simple Emax model).

The percentage of 5-HT3RO was simulated as a function of palonosetron concentration after oral administration of 0.5-mg palonosetron. Mean palonosetron plasma concentration-time data from 22 healthy adults enrolled in the Calcagnile et al. [28] study, who received a single oral NEPA dose in the fasted state, were applied to Eq. 3, where Ct represents palonosetron plasma concentration at any time.

Pivotal phase II clinical study [17]

For the collection of efficacy data, patients completed a diary through the first 120 h after receiving cisplatin, including the following information: timing and duration of each emetic episode, severity of nausea using a 100-mm horizontal visual analog scale, and use of concomitant and rescue medication. In this analysis, the percentages of patients with CR, without emesis, and with “no significant nausea” (NSN) were calculated for the acute period and for each day after (days 2–5), for the full analysis set. The mean time to first emetic episode and the time to treatment failure (time to the first emetic episode or use of rescue medication, whichever occurred first) were determined using the patient-reported data.


Netupitant PK/PD modeling

The sigmoid Emax model parameters from the PET study [27] indicated Emax values greater than 90% in most of investigated brain regions. Estimates of EC50 and γ ranged from 0.2 to 10.2 μg/L and from 0.5 to 1.2 μg/L, respectively, and were characterized by good precision in the striatum. In other brain areas, the limited number of experimental points in the ascending part of the RO vs. plasma concentration curves affected the precision of the EC50 and γ estimates.

PK model parameters reported in Table 1 [28] were estimated by fitting a two-compartment open model (Eq. 3) to the mean plasma concentration-time curves of netupitant from healthy adults receiving 300-mg netupitant as oral NEPA fixed combination [28] and were used to simulate the netupitant plasma concentration-time profile at any time following administration of oral NEPA.
Table 1

PK parameters for netupitant and palonosetron estimated from two-compartmental modeling of plasma concentration-time data

























K 01







λ 1







λ 2







t lag







Mean plasma concentration-time curves of netupitant and palonosetron from 22 healthy adults who received oral NEPA in the fasted state were used for modeling [28]

λ1, λ2, disposition rate constants; A, B, hybrid coefficients; CV, coefficient of variation; K01, absorption rate constant; PK, pharmacokinetics; tlag, lag time

The PK/PD correlation between predicted netupitant NK1RO in all tested brain regions and predicted netupitant plasma concentrations following 300-mg oral netupitant is presented in Fig. 2. Higher and longer-lasting NK1RO were predicted in the occipital cortex, the anterior cingulate, and the frontal cortex, where netupitant RO was greater than or close to 90% up to 120 h postdosing. In the striatum, netupitant NK1RO was predicted to exceed 90% up to approximately 24 h after drug administration, then to decline slowly, reaching 75–80% RO on day 5 postdosing. Netupitant washout from the blood compartment was predicted to be faster than from all brain regions, confirming the high affinity of netupitant for NK1 receptors in the brain.
Fig. 2

Model-predicted netupitant NK1RO in different brain regions and netupitant plasma concentrations as a function of time after administration of 300-mg netupitant. NK1RO, neurokinin-1 receptor occupancy

PD model-predicted NK1RO (Fig. 2) is consistent with experimental values determined by PET after oral administration of 300-mg netupitant [27]. Using the netupitant PK model parameters reported in Table 1 [28], the 90% NK1RO in the striatum was predicted to be attained at a netupitant plasma concentration of 225 ng/mL, reached at 2.23 h after administration of oral NEPA, i.e., earlier than the netupitant peak time, estimated at ∼ 6 h. In addition, 90% NK1RO would be reached within 3 h in other brain regions such as the occipital cortex, the frontal cortex, and the anterior cingulate (Fig. 2).

Palonosetron PK/PD modeling

PK model parameters reported in Table 1 [28] were estimated by fitting a two-compartment open model (Eq. 3) to the mean plasma concentration-time curves of palonosetron from healthy adults receiving 0.5-mg palonosetron as oral NEPA fixed combination [28]. These parameters were used to simulate the palonosetron plasma concentration-time profile at any time following administration of oral NEPA.

PD model-predicted palonosetron 5-HT3RO as a function of PK model-predicted palonosetron plasma concentrations after administration of 0.5-mg palonosetron as oral NEPA indicated that 90% 5-HT3RO in tissues is expected to be attained at a palonosetron plasma concentration of 188 ng/L, reached at 1.05 h after administration of oral NEPA, i.e., earlier than the palonosetron peak concentration of 693 ng/L, estimated at 5.2 h.

The PK/PD correlation between predicted palonosetron 5-HT3RO and predicted palonosetron plasma concentrations as a function of time is presented in Fig. 3. Palonosetron 5-HT3RO was predicted to exceed 90% up to approximately 3 days after drug administration, and then it declined slowly, reaching a RO of approximately 80% on day 5 postdosing. Palonosetron washout from the blood compartment was predicted to be faster than from 5-HT3 receptors in tissues because of the high affinity of palonosetron for 5-HT3 receptors.
Fig. 3

Model-predicted palonosetron 5-HT3RO and predicted palonosetron plasma concentrations as a function of time after administration of 0.5-mg palonosetron. 5-HT3RO, 5-hydroxytryptamine-3 receptor occupancy

Pivotal phase II clinical study

The time to first treatment failure for any patient treated with oral NEPA was 8 h, with a mean time to treatment failure of 114.2 h [17]. The time to the first emetic episode for any oral NEPA-treated patient was also 8 h, with a mean time to first emesis of 114.4 h. The time to the first administration of rescue medication was 95 h, and the mean time was 119.8 h. In the acute phase, for patients receiving NEPA prophylaxis, the rates of no emesis, NSN, and CR were 99% for each, with daily rates of no emesis and NSN of ≥ 95% on days 2–5.


The prevention of acute CINV is mainly dependent on inhibition of 5-HT3 receptors by 5-HT3RAs, while delayed CINV control is associated with NK1 receptor inhibition by NK1RAs [4]. The pivotal clinical study included in this analysis [17] previously demonstrated the superiority of oral NEPA vs oral palonosetron in the rate of acute CR, suggesting that the NK1RA component of the fixed combination, netupitant, may also contribute to the prevention of CINV in the acute period. The present analysis predicted that palonosetron may occupy 90% of 5-HT3 receptors at a plasma concentration of 188 ng/L within 1.05 h after dosing, while netupitant may reach the therapeutic threshold of 90% RO in the striatum [23] at a plasma concentration of 225 ng/mL which is reached as early as 2.23 h after administration. These results further support the role of both components of NEPA in CINV control during the acute phase.

Cisplatin-associated acute nausea and vomiting has been shown to start within the first 4 h after initiation of chemotherapy, and to reach a peak between 4 to 10 h [31]. Here, > 90% of 5-HT3 and of striatal NK1 receptors were predicted to be occupied at 1.05 and 2.23 h, respectively, postadministration of oral NEPA, thus before the start of emetic episodes associated with cisplatin treatment. Accordingly, clinical data showed that the time to first treatment failure following cisplatin administration for any patient among the 135 patients in the oral NEPA group was 8 h. Therefore, reducing the time of administration of NEPA to less than 1 h prior to the administration of cisplatin would not be expected to impact its antiemetic efficacy in the acute phase. In addition, > 90% occupancy of 5-HT3 and of striatal NK1 receptors was predicted to be sustained over approximately 72 and 24 h, respectively, after oral NEPA administration. This prolonged RO also suggests that increasing the time of administration of NEPA to more than 1 h before cisplatin administration would not affect its antiemetic activity.

The antiemetic activity of oral NEPA is sustained in the delayed phase, with a daily CR rate ranging from 96 to 98% on days 2–5 [17]. Although a 90% occupancy of striatal NK1 receptors has been assumed as the threshold to reach antiemetic activity [23], it seems that this level does not need to be sustained over the entire delayed period to exert antiemetic control, since on day 4 a 98% CR rate was attained [17] with an estimated NK1RO in the striatum of 78% (Fig. 2). Noteworthy, in other brain regions such as the occipital cortex and the anterior cingulate, 90% NK1RO was exceeded up to 120 h after NEPA administration. Previous studies have shown that palonosetron and netupitant can act synergistically on the inhibition of the substance P signaling pathway [13, 33]. Palonosetron can inhibit crosstalk between the NK1 and 5-HT3 receptor signaling pathways and induce 5-HT3 receptor internalization, which may result in prolonged inhibition of NK1 and 5-HT3 receptor function/signaling pathways [13].

Overall, the results presented here suggest a potential for flexibility in the administration timing of NEPA administered immediately before chemotherapy. Administration of NEPA closer to the time of chemotherapy would most likely not affect delayed CINV control, as maintaining ≥ 90% NK1RO in the striatum, surrogate marker for effective NK1RA interaction in the area postrema and the nucleus tractus solitarius, does not seem to be required for antiemetic efficacy.

Some limitations of this study include the small number of subjects involved in the PET study with netupitant; the fact that the PET study analyzed the interaction with NK1 receptors following administration of netupitant as single agent; the assumption of the adequacy of a sigmoid Emax model to describe the interaction of palonosetron with the 5-HT3 receptor; and the assumption of the 90% 5-HT3RO threshold to establish 5-HT3RA antiemetic activity for palonosetron. In addition, the data used to develop the PK and PD models, as well as the clinical trial results used to establish potential correlations with clinical antiemetic efficacy, were obtained from independent studies analyzing different subject or patient populations. These limitations and assumptions appear to be acceptable in light of the good correlation between model-predicted (Fig. 2) and observed NK1RO [27] in the different brain regions. In addition, the degree of NK1 and 5-HT3RO correlated well with the described antiemetic effects of NEPA in clinical trials. This retrospective analysis using PK/PD modeling allows generation of accurate predictions about the clinical effects of the timing of oral NEPA administration rapidly and in a noncostly manner that can be used as guidance for optimization of antiemetic administration in future clinical studies. Ultimately, a prospective clinical validation of these results would be required. In fact, a noninferiority study (in terms of CR rate) in cancer patients to examine two different administration times of NEPA relative to the first dose of HEC has been approved and will shortly begin accrual.

In conclusion, the PK/PD modeling and clinical data presented herein suggest that moving the timing of oral NEPA administration closer to chemotherapy initiation would probably not result in a loss of efficacy and could enhance the convenience of the administration. Prospective clinical validation is warranted to confirm these indications.



The authors thank patients, investigators, and the study teams. Editorial and medical writing assistance was provided by Iratxe Abarrategui, PhD, CMPP, and Joanne Franklin, PhD, CMPP, of TRM Oncology, The Hague, The Netherlands, and funded by Helsinn Healthcare SA, Lugano, Switzerland. The authors are fully responsible for all content and editorial decisions for this manuscript.

Source of funding

The trials described within this paper were sponsored by Helsinn Healthcare SA, Lugano, Switzerland.

Compliance with ethical standards

Conflict of interest

Lee Schwartzberg: consultant for Amgen, Helsinn, NanoString, Napo, Pfizer, Taiho, Genentech/Roche, BMS, Genomic Health, Myriad, AstraZeneca; has received nonfinancial support from AbbVie, AstraZeneca, Helsinn, Merck, Novartis, Bayer, Celgene, Lilly, BMS, Genentech, Pfizer; has received institutional grants from BMS, Novartis, and MedImmune.

Matti Aapro: advisor for Eisai, Helsinn, Merck, Mundipharma, Roche, and Tesaro; honoraria from Eisai, Helsinn, Merck, Mundipharma, Roche, and Tesaro; and has received grants from Helsinn, Merck, Roche, and Tesaro.

Sally Baron-Hay: honoraria from AstraZeneca, Novartis, and Pfizer; advisor for AstraZeneca, Novartis, and Pfizer.

Alberto Bernareggi: Helsinn Healthcare SA employee.

Ethical approval

For this type of study, formal consent is not required.


  1. 1.
    Grassi L, Bernardi MA, Ruffilli F, Meggiolaro E, Andritsch E, Sirgo A, Caruso R, Juan Linares E, Bellé M, Massarenti S, Nanni MG, Psycho-Oncology IOR-IRST, UniFE Psychiatry Co-Authors (2015) Role of psychosocial variables on chemotherapy-induced nausea and vomiting and health-related quality of life among cancer patients: a European study. Psychother Psychosom 84:339–347CrossRefGoogle Scholar
  2. 2.
    Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34:557–565CrossRefGoogle Scholar
  3. 3.
    Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318:197–198CrossRefGoogle Scholar
  4. 4.
    Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356–1367CrossRefGoogle Scholar
  5. 5.
    Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1081–1090CrossRefGoogle Scholar
  6. 6.
    Bošnjak SM, Gralla RJ, Schwartzberg L (2017) Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists. Support Care Cancer 25:1661–1671CrossRefGoogle Scholar
  7. 7.
    Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240–3261CrossRefGoogle Scholar
  8. 8.
    National Comprehensive Cancer Network (2018) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Antiemesis. Version 3.2018. Accessed 08 Aug 2018
  9. 9.
    Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MASCC/ESMO Consensus Conference Copenhagen 2015 (2016) MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27:v119–v133CrossRefGoogle Scholar
  10. 10.
    Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39:1074–1080CrossRefGoogle Scholar
  11. 11.
    Lummis SC (2012) 5-HT(3) receptors. J Biol Chem 287:40239–40245CrossRefGoogle Scholar
  12. 12.
    Higgins GA, Kilpatrick GJ, Bunce KT, Jones BJ, Tyers MB (1989) 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 97:247–255CrossRefGoogle Scholar
  13. 13.
    Rojas C, Raje M, Tsukamoto T, Slusher BS (2014) Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol 722:26–37CrossRefGoogle Scholar
  14. 14.
    Roila F, Warr D, Clark-Snow RA, Tonato M, Gralla RJ, Einhorn LH, Herrstedt J (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13:104–108CrossRefGoogle Scholar
  15. 15.
    Geling O, Eichler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294CrossRefGoogle Scholar
  16. 16.
    Kris MG, Gralla RJ, Clark RA, Tyson LB, O’Connell JP, Wertheim MS, Kelsen DP (2005) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379–1384CrossRefGoogle Scholar
  17. 17.
    Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340–1346CrossRefGoogle Scholar
  18. 18.
    Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333CrossRefGoogle Scholar
  19. 19.
    Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333–1339CrossRefGoogle Scholar
  20. 20.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098CrossRefGoogle Scholar
  21. 21.
    Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119CrossRefGoogle Scholar
  22. 22.
    Akynzeo® (netupitant and palonosetron) [prescribing information] (2018) Dublin, Ireland: Helsinn Birex Pharmaceuticals. Accessed 8 Aug 2018
  23. 23.
    Bergström M, Hargreaves RJ, Burns HD, Goldberg MR, Goldberg MR, Sciberras D, Reines SA, Petty KJ, Ogren M, Antoni G, Långström B, Eskola O, Scheinin M, Solin O, Majumdar AK, Constanzer ML, Battisti WP, Bradstreet TE, Gargano C, Hietala J (2004) Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 55:1007–1012CrossRefGoogle Scholar
  24. 24.
    Nakamura H, Yokoyama H, Takayanagi R, Yoshimoto K, Nakajima A, Okuyama K, Iwase O, Yamada Y (2015) Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin. Eur J Drug Metab Pharmacokinet 40:39–44CrossRefGoogle Scholar
  25. 25.
    Martin M (1996) The severity and pattern of emesis following different cytotoxic agents. Oncology 53:26–31CrossRefGoogle Scholar
  26. 26.
    Hesketh P (1996) Management of cisplatin-induced delayed emesis. Oncology 53:73–77CrossRefGoogle Scholar
  27. 27.
    Spinelli T, Calcagnile S, Giuliano C, Rossi G, Lanzarotti C, Mair S, Stevens L, Nisbet I (2014) Netupitant PET imaging and ADME studies in humans. J Clin Pharmacol 54:97–108CrossRefGoogle Scholar
  28. 28.
    Calcagnile S, Lanzarotti C, Gutacker M, Jakob-Rodamer V, Peter Kammerer K, Timmer W (2015) Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: a randomized, open-label, crossover phase 1 study. Clin Pharmacol Drug Dev 4:377–386CrossRefGoogle Scholar
  29. 29.
    Wong EH, Clark R, Leung E, Loury D, Bonhaus DW, Jakeman L, Parnes H, Whiting RL, Eglen RM (1995) The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 114:851–859CrossRefGoogle Scholar
  30. 30.
    Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher B (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107:469–478CrossRefGoogle Scholar
  31. 31.
    Morrow GR, Hickok JT, Rosenthal SN (1995) Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Cancer 76:343–357CrossRefGoogle Scholar
  32. 32.
    US Food and Drug Administration. (2012) Draft Guidance for Industry. Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Accessed 15 June 2018
  33. 33.
    Thomas AG, Stathis M, Rojas C, Slusher BS (2014) Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res 232:2637–2644CrossRefGoogle Scholar

Copyright information

© The Author(s) 2019

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Sally Baron-Hay
    • 1
    Email author
  • Matti Aapro
    • 2
  • Alberto Bernareggi
    • 3
  • Lee Schwartzberg
    • 4
  1. 1.Royal North Shore HospitalSt LeonardsAustralia
  2. 2.Genolier Cancer CentreClinique de GenolierGenolierSwitzerland
  3. 3.Helsinn Healthcare SALuganoSwitzerland
  4. 4.West Cancer CenterMemphisUSA

Personalised recommendations